poisar

Stock

Galectin Therapeutics Inc. GALT

$3.51-0.57%

Overview

GALT market data

Price History

GALT price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.48
Diluted earnings per share over the trailing twelve months.
Beta
0.36
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.03 – $7.13
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $316.7M · P/B 46.88.

Company News

9 captured
Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) EstimateBenzinga · Aug 14, 2026, 12:13 PM
8-K filing — GALECTIN THERAPEUTICS INC (GALT)SEC EDGAR · Aug 14, 2026, 11:55 AM
Galectin Therapeutics Converts ~$105.8M Of Debt Into ~34.4M Shares At Blended Average Conversion Price Of ~$3.07 Per ShareBenzinga · Aug 4, 2026, 12:05 PM
Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 14, 2026, 4:38 PM
Top 3 Health Care Stocks That May Keep You Up At Night In JuneBenzinga · Jun 30, 2026, 1:00 PM
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price TargetBenzinga · Jun 23, 2026, 4:40 PM
Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For Its Belapectin To Treat Patients With Metabolic Dysfunction-associated Steatohepatitis Cirrhosis, Portal HypertensionBenzinga · Jun 23, 2026, 12:15 PM
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH CirrhosisGlobenewswire Inc · May 27, 2026, 12:15 PM
Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) EstimateBenzinga · May 15, 2026, 12:20 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock